儿童社区获得性肺炎短疗程抗菌治疗:SAFER随机临床试验
SAFER研究是一项两中心、平行组、非劣效性随机临床试验,纳入6月龄至10岁、无需住院的社区获得性肺炎患儿,比较5天高剂量阿莫西林后5天安慰剂与10天高剂量阿莫西林的疗效。主要结局为14至21天临床治愈率,符合方案分析显示干预组88.6%对对照组90.8%(风险差-0.016,97.5%置信下限-0.087),意向性分析显示85.7%对84.1%(风险差0.023,97.5%置信下限-0.061),短疗程与标准疗程相当。
要点
- 对于无需住院的既往健康儿童社区获得性肺炎,5天高剂量阿莫西林后安慰剂与10天疗程的临床治愈率相当。
- 符合方案分析临床治愈率干预组88.6%、对照组90.8%,风险差-0.016(97.5%置信下限-0.087)。
- 意向性分析临床治愈率干预组85.7%、对照组84.1%,风险差0.023(97.5%置信下限-0.061)。
核心结论
- 短疗程抗生素治疗(5天高剂量阿莫西林后5天安慰剂)与标准疗程(10天高剂量阿莫西林)相比,在无需住院的既往健康儿童社区获得性肺炎中临床治愈率相当。
- 临床实践指南应考虑推荐5天阿莫西林治疗儿童肺炎管理,以符合抗菌药物管理原则。
研究设计与样本
- SAFER研究为两中心、平行组、非劣效性随机临床试验,包括2012年12月1日至2014年3月31日的单中心预试验和2016年8月1日至2019年12月31日的主要研究,地点为McMaster儿童医院和东安大略儿童医院急诊科。
- 纳入标准为6月龄至10岁、48小时内发热、有呼吸道症状、胸部X线表现符合肺炎且主要诊断为肺炎的儿童;排除需要住院、有易致严重疾病或非典型肺炎合并症、或既往使用过β-内酰胺类抗生素的儿童。
- 研究 staff、参与者和结局评估者对治疗分配设盲;共281名参与者,中位年龄2.6岁(四分位距1.6-4.9),279名记录性别者中男孩160名(57.7%)。
主要发现
- 符合方案分析中,干预组114名儿童中101名(88.6%)达到临床治愈,对照组109名中99名(90.8%)达到临床治愈,风险差-0.016(97.5%置信下限-0.087)。
- 意向性分析中,干预组126名中108名(85.7%)在14至21天达到临床治愈,对照组126名中106名(84.1%)达到临床治愈,风险差0.023(97.5%置信下限-0.061)。
关键数值与推荐
- 干预组为5天高剂量阿莫西林治疗后5天安慰剂,对照组为5天高剂量阿莫西林后5天另一种制剂的高剂量阿莫西林。
- 主要结局为14至21天临床治愈。
临床怎么用
- 对于无需住院的既往健康儿童社区获得性肺炎,可考虑使用5天高剂量阿莫西林短疗程方案,符合抗菌药物管理原则。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Community-acquired pneumonia (CAP) is a common occurrence in childhood; consequently, evidence-based recommendations for its treatment are required. OBJECTIVE: To determine whether 5 days of high-dose amoxicillin for CAP was associated with noninferior rates of clinical cure compared with 10 days of high-dose amoxicillin. DESIGN, SETTING, AND PARTICIPANTS: The SAFER (Short-Course Antimicrobial Therapy for Pediatric Respiratory Infections) study was a 2-center, parallel-group, noninferiority randomized clinical trial consisting of a single-center pilot study from December 1, 2012, to March 31, 2014, and the follow-up main study from August 1, 2016, to December 31, 2019 at the emergency departments of McMaster Children's Hospital and the Children's Hospital of Eastern Ontario. Research staff, participants, and outcome assessors were blinded to treatment allocation. Eligible children were aged 6 months to 10 years and had fever within 48 hours, respiratory symptoms, chest radiography findings consistent with pneumonia as per the emergency department physician, and a primary diagnosis of pneumonia. Children were excluded if they required hospitalization, had comorbidities that would predispose them to severe disease and/or pneumonia of unusual origin, or had previous β-lactam antibiotic therapy. Data were analyzed from March 1 to July 8, 2020. INTERVENTIONS: Five days of high-dose amoxicillin therapy followed by 5 days of placebo (intervention group) vs 5 days of high-dose amoxicillin followed by a different formulation of 5 days of high-dose amoxicillin (control group). MAIN OUTCOMES AND MEASURES: Clinical cure at 14 to 21 days. RESULTS: Among the 281 participants, the median age was 2.6 (interquartile range, 1.6-4.9) years (160 boys [57.7%] of 279 with sex listed). Clinical cure was observed in 101 of 114 children (88.6%) in the intervention group and in 99 of 109 (90.8%) in the control group in per-protocol analysis (risk difference, -0.016; 97.5% confidence limit, -0.087). Clinical cure at 14 to 21 days was observed in 108 of 126 (85.7%) in the intervention group and in 106 of 126 (84.1%) in the control group in the intention-to-treat analysis (risk difference, 0.023; 97.5% confidence limit, -0.061). CONCLUSIONS AND RELEVANCE: Short-course antibiotic therapy appeared to be comparable to standard care for the treatment of previously healthy children with CAP not requiring hospitalization. Clinical practice guidelines should consider recommending 5 days of amoxicillin for pediatric pneumonia management in accordance with antimicrobial stewardship principles. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02380352.
引用
- Pernica JM, Harman S, Kam AJ, et al. Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial. JAMA Pediatr. 2021. PMID: 33683325. doi:10.1001/jamapediatrics.2020.6735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。